Aeterna Zentaris logo

Aeterna ZentarisNASDAQ: AEZS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

10 May 2000

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$4.53 M
-94%vs. 3y high
12%vs. sector
-vs. 3y high
-vs. sector
-85%vs. 3y high
20%vs. sector
-85%vs. 3y high
35%vs. sector

Price

regular market | Thu, 10 Oct 2024 13:30:00 GMT
$3.73(0.00%)

Dividend

No data over the past 3 years
$2.34 M-$1.42 M

Analysts recommendations

Institutional Ownership

AEZS Latest News

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.
globenewswire.com06 August 2024 Sentiment: POSITIVE

TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announces that the Company's name has been changed from “Aeterna Zentaris Inc.” to “COSCIENS Biopharma Inc.”, effective as of August 6, 2024 (the “Name Change”).

Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
globenewswire.com16 July 2024 Sentiment: POSITIVE

TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the "AGSM") held today.

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
globenewswire.com13 June 2024 Sentiment: POSITIVE

Company expects to report top-line data and complete study results in Q3 2024 TORONTO, ONTARIO, June 13, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the clinical completion of its Phase 3 safety and efficacy study AEZS-130-P02 (the "DETECT-trial") evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency ("CGHD"). The Company confirms that the last patient conducted the last study visit successfully in Europe on June 13, 2024.

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date
globenewswire.com29 May 2024 Sentiment: NEUTRAL

TORONTO, ONTARIO, May 29, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that it is making an application for an order pursuant to section 133(3) of the Canada Business Corporations Act extending the time for the Company to call and hold its annual meeting of its shareholders to a date that is not later than July 31, 2024 (the “Application”). The Application is scheduled to be heard before a judge of the Ontario Superior Court of Justice, Commercial List (the “Court”) on June 3, 2024 at 11:00 a.m. via videoconference. There can be no assurance that the order sought by Aeterna will be granted.

Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research27 March 2024 Sentiment: NEGATIVE

Aeterna Zentaris (AEZS) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $0.84 per share a year ago.

Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research23 March 2023 Sentiment: POSITIVE

Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 9.68% and 134.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

What type of business is Aeterna Zentaris?

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

What sector is Aeterna Zentaris in?

Aeterna Zentaris is in the Healthcare sector

What industry is Aeterna Zentaris in?

Aeterna Zentaris is in the Biotechnology industry

What country is Aeterna Zentaris from?

Aeterna Zentaris is headquartered in Canada

When did Aeterna Zentaris go public?

Aeterna Zentaris initial public offering (IPO) was on 10 May 2000

What is Aeterna Zentaris website?

https://www.zentaris.com

Is Aeterna Zentaris in the S&P 500?

No, Aeterna Zentaris is not included in the S&P 500 index

Is Aeterna Zentaris in the NASDAQ 100?

No, Aeterna Zentaris is not included in the NASDAQ 100 index

Is Aeterna Zentaris in the Dow Jones?

No, Aeterna Zentaris is not included in the Dow Jones index

When was Aeterna Zentaris the previous earnings report?

No data

When does Aeterna Zentaris earnings report?

Next earnings report date is not announced yet